Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives

John Gubatan, Kian Keyashian, Samuel JS Rubin, Jenny Wang, Cyrus A Buckman, Sidhartha Sinha

Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA; Stanford University School of Medicine, Stanford, CA, USA; Immunology Program, Stanford University School of Medicine, Stanford, CA, USA

Abstract: Leukocyte trafficking to the gastrointestinal tract is recognized to play a role in the pathogenesis of inflammatory bowel disease (IBD). Integrins are expressed on immune cells and interact with cell adhesion molecules (CAM) to mediate leukocyte trafficking. Blockade of the gut-tropic integrin α4β7 and its subunits has been exploited as a therapeutic target in IBD. Natalizumab (anti-α4) is approved for moderate to severe Crohn’s disease (CD), but its use is limited due to potential risk of progressive multifocal leukoencephalopathy. Vedolizumab (anti-α4β7) is approved for the treatment of ulcerative colitis (UC) and CD. It is the most widely used anti-integrin therapy in IBD and has been shown to be effective in both induction and maintenance therapy, with a favorable safety profile. Several models incorporating clinical, genetic, immune, gut microbial, and vitamin D markers to predict response to vedolizumab in IBD have been developed. Etrolizumab (anti-β7) blocks leukocyte trafficking via α4β7 and cell adhesion via αEβ7 integrins. Large phase 3 clinical trials evaluating efficacy of etrolizumab in the induction and maintenance of patients with IBD are underway. Other investigational anti-integrin therapies include abrilumab (anti-α4β7 IgG2), PN-943 (orally administered and gut-restricted α4β7 antagonist peptide), AJM300 (orally active small molecule inhibitor of α4), and ontamalimab (anti-MAdCAM-1 IgG).

Keywords: anti-integrin, inflammatory bowel disease, ulcerative colitis, Crohn’s disease, vedolizumab, natalizumab, etrolizumab

Introduction

Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic inflammatory disorder of the gastrointestinal tract. The etiology of IBD is unclear, but the current thought is that genetic and environmental factors lead to immune dysregulation, intestinal barrier dysfunction, and loss of tolerance to commensal gut bacteria. The incidence of IBD is increasing worldwide and associated with increased healthcare utilization and poor quality of life. The management of IBD often involves immunosuppressive therapies such as corticosteroids, immunomodulators, small molecules, and biologic agents that inhibit proinflammatory cytokine pathways (e.g., anti-TNF-α, anti-p40 subunit of IL-12/23). More specific therapies that target gut-tropic integrins and block leukocyte trafficking to the gastrointestinal tract provide an alternative therapeutic approach to systematic immunosuppression in IBD. In this review, we explore the role of integrins in leukocyte trafficking to the gut and highlight currently approved and emerging anti-integrin therapies in IBD (summarized in Figure 1).
Role of Integrins in Leukocyte Trafficking to Gastrointestinal Tract and Pathogenesis of Inflammatory Bowel Disease

Integrins are cell surface transmembrane glycoproteins that mediate cell–cell interactions and play critical roles in immune cell proliferation, signaling, and trafficking. Integrins consist of heterodimers involving α and β subunits that bind to cell adhesion molecules (CAM) on other cell types or to the extracellular matrix. Immune cells express integrins that bind to tissue-specific CAM which mediates their trafficking from circulation or lymphoid tissue to specific peripheral tissue including the gastrointestinal tract (gut-associated lymphoid tissue, GALT). Several integrins have been characterized to confer specific trafficking to the gut (“gut-tropic integrins”). The integrin αLβ2 (LFA-1) is expressed by lymphocytes and natural killer (NK) cells and interacts with intercellular adhesion molecules (ICAMs) to mediate lymphocyte trafficking to mesenteric lymph nodes. The integrin α4β1 (VLA-4) is expressed on most leukocytes and neutrophils and interacts with vascular cell adhesion molecule 1 (VCAM-1). The α4β1 integrin plays a role in the homing of memory and effector T lymphocytes to the brain as well as to inflamed intestinal tissue. The α4β7 integrin heterodimer of memory T and B cells is a cell-surface glycoprotein that is critical for leukocyte homing in the gut. The α4β7 integrin interacts with mucosal addressin-cell adhesion molecule 1 (MAdCAM-1) expressed on high endothelial venules in GALT, which is expressed on the intestinal vascular endothelium; this interaction plays an important role in immune surveillance of the gastrointestinal tract and the gut-selective nature of lymphocyte trafficking as it enables lymphocytes to travel across the vascular endothelial barrier to GALT or intestinal lamina propria. The αE integrin (also known as CD103) can dimerize with the β7 integrin to form αEβ7 which binds to its ligand E-cadherin. αEβ7 expression has been demonstrated on various immune cells including intraepithelial T lymphocytes and dendritic cells (DCs). αEβ7 expression on intraepithelial lymphocytes enables their retention on the epithelial layer of the intestinal tract.

Since integrins mediate trafficking and retention of immune cells to the gastrointestinal tract, it is not surprising that they are implicated in the pathogenesis of IBD. A prior genome-wide association study demonstrated that IBD was associated with immune activation of multiple integrin genes (ITGA4, ITGB8, ITGAL, ICAM1). These four loci were also associated with risk of IBD. Patients with IBD have been shown to have upregulated gut-tropic integrins and cell adhesion molecules in inflamed intestinal tissue. For example, circulating α4β7+ CD4 T cells are

Figure 1 Summary of current and investigational anti-integrin therapies and their targets in inflammatory bowel disease. Created with BioRender.com.
increased among patients with UC and CD.\textsuperscript{18,19} Likewise, VCAM-1 and MAdCAM-1 are upregulated in IBD.\textsuperscript{20} These early observations provided a rationale for blockade of integrins or cell adhesion molecules as a therapeutic target in IBD. In early preclinical studies, blockade with either anti-β7 or anti-MAdCAM-1 monoclonal antibodies significantly reduced the severity of colitis in murine T cell transfer models of IBD.\textsuperscript{21} Similarly, antibody blockade of α4 or α4β7 improved histologic inflammation in a cotton-top tamarin monkey colitis model.\textsuperscript{22} The remainder of the review will focus on human studies summarizing current evidence of anti-α4 (natalizumab), anti-α4β7 (vedolizumab), anti-β7 (etrolizumab), and other emerging anti-integrin therapies for the management of IBD.

**Anti-Integrin Therapy: Natalizumab (Anti-α4)**

Natalizumab (Tysabri, Elan Pharmaceuticals, and Biogen Idec) is a humanized IgG4 monoclonal antibody against the α4 subunit of the integrin heterodimer, effectively targeting α4β1 and α4β7, thereby inhibiting leukocyte adhesion and migration from the vasculature into tissue.\textsuperscript{23} Initially FDA-approved for multiple sclerosis, natalizumab was also shown to be potentially clinically effective and safe in moderate to severe CD during early phase studies.\textsuperscript{24,25} Subsequent FDA approval for moderate to severe CD was based on ENACT-1 and ENACT-2, two randomized, double-blind, placebo-controlled trials conducted at 142 centers between 12/2001 and 3/2004.\textsuperscript{26} ENACT-1, which enrolled 905 patients with moderate to severe CD, demonstrated 10-week CDAI-based clinical response for natalizumab to be 56% versus 49% for placebo (\(P=0.05\)). The subsequent ENACT-2, which enrolled 339 patients that were responsive to natalizumab from ENACT-1, showed a statistically significant sustained response through week 36 (61% versus 28%, \(P<0.001\)) and sustained remission (44% versus 26%, \(P=0.003\)); 54% with initial response continued to respond at week 60. After approval, real-world data from tertiary referral centers confirmed clinical response of up to 60% at 1 year, with particular benefit in non-penetrating CD.\textsuperscript{27-29}

In 2005, case reports surfaced of the association between natalizumab and progressive multifocal leukoencephalopathy (PML) in 2 patients with multiple sclerosis and 1 patient with CD.\textsuperscript{30,31} The disorder resulting in lytic demyelination in the central nervous system, with known pathogenetic association with the JC virus, results in up to a 25% mortality and permanent neurologic deficits.\textsuperscript{32} In the initial case report in CD, JC virus DNA was first noted 3 months after starting natalizumab, with dramatic increase subsequently.\textsuperscript{31} In the larger IBD population studied, tertiary center data showed seropositivity for JC virus to be above 65% in those tested, with risk factors including previous thiopurine use. Seroconversion was also shown to occur at 4.5% after 22 months of treatment.\textsuperscript{33}

Initial risk stratification algorithms revealed higher risk of PML with JC virus antibody positivity, use of immunosuppression, and longer treatment duration beyond 2 years. More recently, patient-level data from 4 large open-label studies of >37,000 natalizumab-treated patients showed the point incidence of PML to be 0.4%, with 99% of patients testing positive for JC virus 6 months before the diagnosis of PML.\textsuperscript{34} This study also showed that with JC virus antibody negativity, <0.07/1000 patients develop PML. In those with JC virus antibody positivity, 1.7% develop PML over 6 years if not on additional immunosuppression, with rates of 2.7% if concomitant immunosuppression was used. This association led to suspension of the drug for clinical use in 2005, with subsequent reintroduction through the TOUCH program (Tysabri Outreach: Unified Commitment to Health). Given safety concerns, the place for natalizumab in management of moderate to severe CD seems limited. Natalizumab is currently not approved for IBD in Europe.\textsuperscript{35}

**Anti-Integrin Therapy: Vedolizumab (Anti-α4β7)**

Vedolizumab (Takeda) is a humanized monoclonal IgG1 antibody that targets the α4β7 heterodimer. The antibody selectively blocks α4β7:MAdCAM-1 interactions—preventing leukocyte adhesion to intestinal endothelium—but does not affect α4β1:VCAM-1 interactions.\textsuperscript{36} Vedolizumab is FDA-approved for induction and maintenance therapy in patients with CD and CD. In GEMINI 1 (NCT00783718), two integrated randomized, double-blind, placebo-controlled trials of vedolizumab in patients with UC with active disease were performed.\textsuperscript{37} In the induction therapy trials, 374 patients (cohort 1) received vedolizumab or placebo intravenously at weeks 0 and 2, and 521 patients (cohort 2) received open-label vedolizumab at weeks 0 and 2, and response (defined by a reduction in Mayo score of at least 3 points and a decrease of at least 30% from baseline) was assessed at week 6. Response rates at week 6 were 47.1% and 25.5% among patients in the vedolizumab group and placebo group,
respectively ($P<0.001$). In the maintenance therapy trials, patients in either cohort who had a response to vedolizumab at week 6 were randomly assigned to continue receiving vedolizumab every 8 or 4 weeks, or to switch to placebo for up to 52 weeks. At week 52, 41.8% of patients who continued to receive vedolizumab every 8 weeks and 44.8% of patients who continued to receive vedolizumab every 4 weeks were in clinical remission, as compared with 15.9% of patients who switched to placebo ($P<0.001$). In GEMINI 2 (NCT00783692), an integrated study with induction and maintenance trials with vedolizumab was performed in patients with active CD. The induction trials included 368 patients who were randomly assigned to receive vedolizumab or placebo at weeks 0 and 2 (cohort 1), and 747 patients who received open-label vedolizumab at weeks 0 and 2 (cohort 2). Disease response (based on Crohn’s Disease Activity Index [CDAI]) was assessed at week 6. At week 6, 14.5% of the patients in cohort 1 and 17.7% of patients in cohort 2 were in clinical remission. In the maintenance trial, 461 patients who previously responded to vedolizumab were randomly assigned to receive placebo or vedolizumab every 8 or 4 weeks until week 52. Among patients who had a response to induction therapy, clinical remission rates at week 52 were 39% and 36.4% for patients assigned to vedolizumab every 8 weeks and every 4 weeks, as compared with 21.6% assigned to placebo ($P<0.001$ and $P=0.004$ for the two vedolizumab groups, respectively, vs placebo).

Given its gut-selective properties and less systemic effects, vedolizumab may have a more favorable safety profile compared to other biologics. Safety data integrated from 6 clinical trials with vedolizumab including more than 2800 patients demonstrated no increased risk of any infection. Vedolizumab was not associated with increased risk of serious or opportunistic infections—including sepsis, tuberculosis, *Listeria* meningitis, and clostridial infections—or increased malignancy when compared with placebo. Serious clostridial infections, sepsis, and tuberculosis were reported infrequently, and no cases of PML were observed. To date, only one case of PML in a vedolizumab-treated patient has been reported in the post-marketing setting. Of note, this patient had multiple contributory factors, including human immunodeficiency virus infection with a CD4 count of 300 cells/mm$^3$ and prior and concomitant immunosuppression. In the phase 3, open-label GEMINI long-term safety (LTS) study, which enrolled 2243 patients with IBD who received vedolizumab 300 mg IV every 4 weeks, serious adverse events were reported for 31% (UC) and 41% (CD) of patients over 8 years. There were no new trends for infections, malignancies, infusion-related reactions, or cases of PML in these studies. Long-term clinical response rates with vedolizumab maintenance therapy were 33% and 28% for UC and CD, respectively. In the VARSITY clinical trial comparing vedolizumab versus adalimumab in moderate to severe UC, vedolizumab was found to be superior to adalimumab for the outcome of clinical remission and endoscopic response, but not corticosteroid-free clinical remission. In the multicenter cohort study nested in the OBSERV-IBD cohort consisting of 294 patients with IBD on vedolizumab, 34 (13.8%) patients, without any extraintestinal manifestation at baseline, developed incident cases of inflammatory arthralgia/arthritis.

In recent years, there has been an increasing emphasis on identifying clinical and biological markers that accurately predict patient response to certain IBD treatments. This is particularly important for tailoring the treatment regimen to each patient. Several studies have evaluated utility of prediction models for response to vedolizumab therapy. For both UC and CD patients, baseline disease activity was identified as an independent predictor of vedolizumab response. Specifically, the GEMINI trials found that patients with a <9 baseline Mayo score and ≤330 CDAI score demonstrated higher rates of achieving clinical remission (at weeks 6 and 54) than the placebo group. Subsequent cohort studies have shown that patients with higher disease activity scores are associated with lower rates of clinical remission. High baseline levels of systemic and intestinal inflammation are associated with lower rates of remission and clinical response to vedolizumab. Elevated C-reactive protein (CRP) was associated with lower rates of clinical response or remission at week 14 of vedolizumab treatment. Conversely, lower baseline CRP levels were associated with higher rates of clinical remission at week 54. Initial clinical response to vedolizumab is a predictor of long-term treatment response; those who demonstrate early responses to vedolizumab treatment have higher rates of also achieving long-term responses—specifically, steroid-free clinical remission. Prior anti-TNF failure is a recognized risk factor for response to vedolizumab. The GEMINI trials found that anti-TNF-naïve UC and CD patients tend to have higher rates of remission with vedolizumab than those who with prior anti-TNF exposure. Clinical decision support tools to predict response to vedolizumab therapy have been developed and validated. A model including absence of exposure to anti-TNF, disease duration of 2 years or more, baseline
endoscopic score, and baseline albumin concentration predicted corticosteroid-free remission during vedolizumab therapy in patients with UC.\textsuperscript{47} A similar model to predict vedolizumab response in CD was developed by incorporating the absence of previous treatment with an anti-TNF, absence of prior bowel surgery, absence of prior fistulizing disease, baseline level of albumin, and baseline concentration of CRP.\textsuperscript{48} Immune, genetic, and microbial biomarkers to predict vedolizumab response in IBD have also been explored. A prior study\textsuperscript{49} demonstrated that serum cytokines IL-6 and IL-8 could predict clinical response to therapy after 12 months of vedolizumab. A prior study\textsuperscript{50} demonstrated that baseline plasma levels of α4β7 on CD4+ T cells were higher in patients with IBD who responded to vedolizumab versus non-responders. In the same study, changes in integrin expression were not associated with CD response to vedolizumab. In patients with UC, increasing α4β7 levels with vedolizumab was associated with favorable clinical outcomes, whereas increasing α4β1 and αEβ7 correlated with negative outcomes. In a study that performed immunophenotyping of peripheral and mucosal immune cells in IBD patients on vedolizumab, the authors found that vedolizumab was not associated with abundance or phenotype of T cells but rather with significant changes in macrophage populations.\textsuperscript{51} Another study\textsuperscript{52} demonstrated that ileal biopsies from patients with CD with intestinal epithelial death caused by innate immune-driven pyroptosis predicted endoscopic improvement and clinical response to vedolizumab. A study using RNA-seq analysis of colon biopsies from patients with IBD\textsuperscript{53} demonstrated that baseline expression levels of four genes (PIWIL1, MAATS1, RGS13, and DCHS2) predicted endoscopic remission after vedolizumab, but not anti-TNF treatment. In this same study,\textsuperscript{53} monocytes, M1 macrophages, CD4 memory T cells, and T regulatory cells were enriched in vedolizumab non-responders, whereas naive B cells were enriched in vedolizumab responders. The role of the gut microbiome in response to vedolizumab in IBD has also been evaluated. One study\textsuperscript{54} assessed disease activity and stool metagenomes at baseline, 14, 30, and 54 weeks; CD patients with greater community α-diversity and higher baseline levels of Roseburia inulinivorans and Burkholderiales species were more likely to be in clinical remission 14 weeks after vedolizumab initiation. The authors hypothesized that greater baseline diversity includes anti-inflammatory microbes and metabolites that promote treatment response. Additionally, 13 biological pathways—citrulline, isoleucine, arginine, and polyamine BCAA synthesis pathways—were significantly enhanced in CD patients who achieved remission.\textsuperscript{54} Finally, a recent study identified low vitamin D status to predict vedolizumab primary non-response during induction and 1-year failure in patients with IBD.\textsuperscript{55} Using single-cell immunophenotyping of peripheral and intestinal immune cells, the authors demonstrated a potential link between serum vitamin D levels and expression of αβ7 on immune cells.

### Anti-Integrin Therapy in Clinical Trials: Etrolizumab (Anti-β7)

Etrolizumab is a monoclonal antibody that blocks cellular adhesion by binding the β7 subunit of both α4β7 and αEβ7 integrins. The α4β7 and αEβ7 integrins function as trafficking molecules that localize leukocytes to inflammatory sites in the gut.\textsuperscript{56} Etrolizumab binds αβ7 and prevents binding to MAdCAM-1, a receptor that is highly upregulated in the intestinal venules of patients with UC and CD. Etrolizumab also binds αEβ7 and prevents interaction with E-cadherin found on intestinal mucosal cells. The αβ7-expressing lymphocytes residing in the gut participate in the inflammatory responses observed in IBD.\textsuperscript{57} Thus, the inhibition of αβ7 results in decreased inflammation and increased retention of leukocytes within the intraepithelial space of the intestinal mucosa.

Etrolizumab was evaluated for safety and tolerability in a phase 1 study involving patients with moderate to severe UC. The patients received etrolizumab either as a single dose (0.3–10 mg/kg) or as three doses (0.5–4 mg/kg) administered every four weeks. The drug was given either intravenously or subcutaneously. There were no significant dose-limiting toxicities, infusion, or injection site reactions in either single or multiple dose groups.\textsuperscript{58} A randomized, placebo-controlled phase 2 study was implemented to determine the drug’s efficacy by enrolling patients with moderate to severe UC in three dosage groups, consisting of (i) etrolizumab 100 mg (nominal) administered every four weeks; (ii) etrolizumab 420 mg at week 0 (loading dose) followed by 300 mg (nominal) at weeks 2, 4, and 8; and (iii) placebo. Patients in the etrolizumab groups were more likely to experience clinical remission at week ten compared to the placebo group. Most patients in clinical remission came from the etrolizumab 100 mg group (n=39), with 21% achieving remission, followed by 10% in the 300 mg LD cohort (n=39), compared with 0% in the
placebo cohort (n=41). Currently, there are several phase 3 clinical trials evaluating etrolizumab in IBD (UC: HIBISCUS I and II, GARDENIA, LAUREL, HICKORY; CD: BERGAMOT) and two open-label extension trials (UC: COTTONWOOD; CD: JUNIPER). In a recent update from phase 3 studies of etrolizumab in patients with moderate to severe UC, etrolizumab effectively induced remission compared to placebo but did not meet its primary endpoint as maintenance therapy. There were no major safety issues in any of the phase 3 studies reported to date.

Concurrent studies evaluating biomarkers for predicting response to etrolizumab in patients with IBD have also been conducted. In a retrospective analysis of data collected from UC patients who participated in a phase 2 placebo-controlled trial of etrolizumab, gene expression levels of GZMA and ITGAE from colon biopsies identified patients who were most likely to benefit from etrolizumab. Furthermore, expression levels decreased with etrolizumab administration in patients with high baseline expression. In a recent study, CD patients experienced a reduction in inflammatory genes and cytotoxic intraepithelial lymphocyte (IEL) gene signatures following etrolizumab therapy.

Other Anti-Integrin Therapies Under Investigation

As selective targeting of gut-tropic cells has been established as a validated approach to the treatment of IBD with reduced extra-intestinal systemic effects, numerous additional anti-integrin therapies are in development. Owing to their combinatorial tissue selectively and established mechanistic understanding, much focus is on the blockade of integrins and their ligands. Considerable efforts are also directed towards other pathways of cellular trafficking, namely the sphingosine-1-phosphate receptor, as well as G-protein coupled receptors (GPCRs) and C-C chemokine receptors (CCRs) in earlier phases of development. These ongoing programs include monoclonal antibodies, as well as additional pharmaceutical modalities, such as small molecules and peptides that have unique pharmacokinetic (PK) and pharmacodynamic (PD) properties.

Abrilumab (AMG 181/MEDI 7183)

Abrilumab is a human anti-α4β7 IgG2 mAb with favorable PK and PD properties amenable to subcutaneous administration. Phase 2b trials of abrilumab were completed for both CD and UC. The phase 2b placebo-controlled RCT for CD included 249 patients with inadequate or lost response to previous therapies, who were dosed with 21 mg, 70 mg, or 210 mg on day 1, week 2, week 4, and every 4 weeks for 24 weeks, with a primary endpoint of remission at week 12 and CDAI at weeks 8 and 12. Although the primary endpoints were not met, treatment groups had higher rates of remission at week 12, safety measures were balanced between treatment and placebo groups, and α4β7 receptor occupancy was sustained. A phase 2 trial with 45 UC patients demonstrated improved remission and safety for abrilumab compared to placebo. A larger phase 2b trial for UC included 354 patients with inadequate or lost response to previous therapies, who were dosed with 21 mg, 70 mg, or 210 mg on day 1, week 2, week 4, and every 4 weeks, with a primary endpoint of remission at week 8. There were significantly higher rates of remission in the two higher-dose treatment groups at 8 weeks compared to placebo, and there were no cases of PML or deaths in the trial. To date, phase 3 trials for abrilumab have not been registered.

PN-943

PN-943 is an orally administered and gut-restricted α4β7 antagonist peptide taking advantage of a topical route of administration. PN-943 is more effective for induction of remission in UC than PTG-100, an earlier-generation orally administered and gut-restricted α4β7 antagonist cysteine knot peptide developed by the same company that preferentially binds activated α4β7 on T cells. A phase 2 trial of PTG-100 was terminated, and a phase 2 trial of PN-943 is underway to evaluate the effects of 150 mg, 450 mg, or placebo twice daily on 12- and 52-week remission in moderate and severe UC (NCT04504383).

Carotegrast Methyl (AJM300)

Carotegrast methyl is an orally active small molecule inhibitor of α4, with demonstrated activity against α4β7 and α4β1. The molecule is dosed thrice daily and characterized by generally mild adverse effects. A phase 2a placebo-controlled RCT in 102 patients with moderately active UC who had inadequate or lost response to previous therapies demonstrated significantly higher rates of clinical remission and mucosal healing at 8 weeks in the treatment compared to placebo group, as well as no serious adverse events, including PML. A smaller trial in CD using significantly lower doses showed no significant difference in CDAI at week 4.
for carotegrast methyl compared to placebo, although the results were published in abstract form only. A phase 3 trial in UC is ongoing (NCT03531892).

**Ontamalimab (PF-00547659 or SHP647)**

Ontamalimab is a subcutaneously administered fully human IgG2x anti-MAdCAM-1 mAb that blocks α4β7 binding to the MAdCAM-1 ligand, with no observed effects on cerebrospinal fluid lymphocytes. The OPERA phase 2 placebo-controlled RCT in patients with active moderate to severe CD enrolled 265 patients with inadequate or lost response to previous therapies. The primary endpoint was reduction in CDAI at week 8 or 12, which was not significantly different between treatment and placebo; however, the remission rate was higher amongst patients with a higher baseline CRP. The TURANDOT phase 2 placebo-controlled RCT in active UC enrolled 357 patients with inadequate or lost response to previous therapies, who were administered one of four different treatment doses or placebo every 4 weeks. The primary endpoint was remission at week 12, which was significantly higher in 3 of 4 treatment groups compared to placebo. Adverse effects were similar across all groups. An open-label dose escalation extension of the TURANDOT trial demonstrated acceptable drug tolerance, with 36.1% of patients experiencing drug-related adverse events (AEs), with the most common serious AE being worsening or ongoing UC, followed by serious infection. Ontamalimab was originally developed by Pfizer, which licensed it out to Shire back in 2016. Takeda later acquired Shire in 2019. At this time, it appears Ontamalimab will not be developed further and is unlikely enter the IBD market as Takeda announced in May 2020 that clinical trials will not restarted after disruptions caused by the COVID-19 pandemic.

**Conclusions and Future Directions**

Antibody blockade of leukocyte trafficking to the gastrointestinal tract with anti-integrin therapy (anti-α4β7) is effective for patients with IBD and is associated with favorable safety profiles. Interestingly, biomarker studies suggest that the therapeutic efficacy of vedolizumab may be mediated by more non-T-cell pathways (eg, macrophages, B cells). The clinical benefit of additional blockade of cellular retention via targeting αEβ7 with etrolizumab remains to be determined. Future studies are needed to further understand the exact mechanisms of anti-integrin therapies in IBD and whether novel anti-integrin pathway approaches (small molecule inhibitors of integrins, inhibition of cell adhesions molecules such as MAdCAM-1, etc.) have a place in the therapeutic armamentarium against IBD.

**Author Contributions**

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

**Funding**

JG is supported by a Chan Zuckerberg Biohub Physician Scientist Scholar Award, NIH NIDDK LRP Award (L30 DK126220), and a Doris Duke Physician Scientist Fellowship Award (Grant #2021091).

**Disclosure**

The authors have no conflicts of interests or financial disclosures relevant to this work.


